世界科学技术-中医药现代化
世界科學技術-中醫藥現代化
세계과학기술-중의약현대화
WORLD SCIENCE AND TECHNOLOGY-MODERNIZATION OF TRADITIONAL CHINESE MEDICINE
2013年
5期
1051-1055
,共5页
金硕果%梁静涛%杨旭红%赵欢%史敏%陈卫银%孙鸿辉%冉宁晶%牟歌童%陈寒冰%杨东东
金碩果%樑靜濤%楊旭紅%趙歡%史敏%陳衛銀%孫鴻輝%冉寧晶%牟歌童%陳寒冰%楊東東
금석과%량정도%양욱홍%조환%사민%진위은%손홍휘%염저정%모가동%진한빙%양동동
补肾活血开窍方%糖尿病所致血管性轻度认知功能障碍%尼莫地平%临床研究
補腎活血開纖方%糖尿病所緻血管性輕度認知功能障礙%尼莫地平%臨床研究
보신활혈개규방%당뇨병소치혈관성경도인지공능장애%니막지평%림상연구
Bushen Huoxue Kaiqiao prescription%vascular mild cognitive impairment%nimodipine%clinical trial
目的:观察补肾活血开窍方治疗糖尿病所致血管性轻度认知功能障碍的临床疗效。方法:将30例糖尿病所致血管性轻度认知功能障碍的患者随机分为治疗组(15例)和对照组(15例),治疗组予以补肾活血开窍方(肉苁蓉10 g、石菖蒲5 g、三七2.5 g)免煎制剂治疗,每天3次,同时服用尼莫地平每次30 mg、一日3次,对照组服用尼莫地平每次30 mg、一日3次,上述治疗持续6个月。治疗前后采用临床痴呆评定量表(CDR)、日常生活能力量表(ADL)、蒙特利尔认知评估北京版(MoCA)及中医症候评分进行评估。结果:治疗后2组均有进步率,治疗组86.70%,对照组33.33%,治疗组总有效率优于对照组(P<0.05)。2组患者中MoCa量表和ADL量表及中医症候评分与同组治疗前比较,差异均有统计学意义(P<0.05),治疗组治疗后优于对照组,2组比较差异有统计学意义(P<0.05)。2组不良事件发生率比较经字2检验无统计学意义。结论:补肾活血开窍方治疗糖尿病所致血管性轻度认知功能障碍临床疗效优于尼莫地平,在改善日常生活能力、认知功能、痴呆程度及中医症候评分方面均优于尼莫地平;不良事件发生率与尼莫地平相当。
目的:觀察補腎活血開纖方治療糖尿病所緻血管性輕度認知功能障礙的臨床療效。方法:將30例糖尿病所緻血管性輕度認知功能障礙的患者隨機分為治療組(15例)和對照組(15例),治療組予以補腎活血開纖方(肉蓯蓉10 g、石菖蒲5 g、三七2.5 g)免煎製劑治療,每天3次,同時服用尼莫地平每次30 mg、一日3次,對照組服用尼莫地平每次30 mg、一日3次,上述治療持續6箇月。治療前後採用臨床癡呆評定量錶(CDR)、日常生活能力量錶(ADL)、矇特利爾認知評估北京版(MoCA)及中醫癥候評分進行評估。結果:治療後2組均有進步率,治療組86.70%,對照組33.33%,治療組總有效率優于對照組(P<0.05)。2組患者中MoCa量錶和ADL量錶及中醫癥候評分與同組治療前比較,差異均有統計學意義(P<0.05),治療組治療後優于對照組,2組比較差異有統計學意義(P<0.05)。2組不良事件髮生率比較經字2檢驗無統計學意義。結論:補腎活血開纖方治療糖尿病所緻血管性輕度認知功能障礙臨床療效優于尼莫地平,在改善日常生活能力、認知功能、癡呆程度及中醫癥候評分方麵均優于尼莫地平;不良事件髮生率與尼莫地平相噹。
목적:관찰보신활혈개규방치료당뇨병소치혈관성경도인지공능장애적림상료효。방법:장30례당뇨병소치혈관성경도인지공능장애적환자수궤분위치료조(15례)화대조조(15례),치료조여이보신활혈개규방(육종용10 g、석창포5 g、삼칠2.5 g)면전제제치료,매천3차,동시복용니막지평매차30 mg、일일3차,대조조복용니막지평매차30 mg、일일3차,상술치료지속6개월。치료전후채용림상치태평정량표(CDR)、일상생활능역량표(ADL)、몽특리이인지평고북경판(MoCA)급중의증후평분진행평고。결과:치료후2조균유진보솔,치료조86.70%,대조조33.33%,치료조총유효솔우우대조조(P<0.05)。2조환자중MoCa량표화ADL량표급중의증후평분여동조치료전비교,차이균유통계학의의(P<0.05),치료조치료후우우대조조,2조비교차이유통계학의의(P<0.05)。2조불량사건발생솔비교경자2검험무통계학의의。결론:보신활혈개규방치료당뇨병소치혈관성경도인지공능장애림상료효우우니막지평,재개선일상생활능력、인지공능、치태정도급중의증후평분방면균우우니막지평;불량사건발생솔여니막지평상당。
This study was aimed to observe clinical efficacy of Bushen Huoxue Kaiqiao (BSHXKQ) treatment of diabetes-induced vascular mild cognitive impairment . A total of 30 cases of diabetes-induced vascular mild cognitive impairment were randomly divided into the treatment group ( 15 cases ) and the control group ( 15 cas-es). The treatment group received free-fried BSHXKQ prescription (Cistanche 10 g, Shichangpu 5 g, Sanqi 2 . 5 g ) for treatment 3 times a day , and in combination of 30 mg of nimodipine , 3 times a day . In the con-trol group , 30 mg of nimodipine was orally administrated 3 times a day . The treatment was continued for 6 months. Clinical Dementia Rating (CDR), Activity of Daily Living Scale (ADL), Montreal Cognitive Assessment Beijing Edition ( MoCA ) and TCM Syndrome Score were used in the evaluation before and after the treatment . The results showed that the rate of progress was in both groups after treatment . In the treatment group , the rate was 86 . 70%, and in the control group the rate was 33 . 33%. The total effective rate in the treatment group was superior to the control group ( P < 0 . 05 ) . There were statistical significances in the MoCa Scale , ADL Scale and TCM Syndrome Score before and after treatment in each group ( P < 0 . 05 ) . The treatment ef-fect in the treatment group was superior to the control group ( P < 0 . 05 ) . There was no statistical significance in the incidence of adverse events in both groups . It was concluded that the effect of BSHXKQ prescription in the treatment of diabetes-induced vascular mild cognitive impairment was superior to nimodipine in improving activities of daily living , cognitive function , degree of dementia and TCM syndrome score . There was no differ-ence in the incidence of adverse events compared with nimodipine .